InMed Pharmaceuticals Files Proxy Materials
Ticker: INM · Form: DEFA14A · Filed: May 29, 2025 · CIK: 1728328
Sentiment: neutral
Topics: proxy-statement, regulatory-filing, pharmaceutical
TL;DR
InMed Pharma filed proxy docs, no fee. Standard stuff.
AI Summary
InMed Pharmaceuticals Inc. filed a Definitive Additional Materials (DEFA14A) on May 29, 2025. This filing is related to their proxy statement and indicates no fee was required for this submission. The company is based in Vancouver, BC, Canada.
Why It Matters
This filing is a routine regulatory submission for InMed Pharmaceuticals, providing additional materials related to their proxy statement, which is crucial for shareholder voting and corporate governance.
Risk Assessment
Risk Level: low — This filing is a routine administrative document and does not contain new financial information or strategic changes that would inherently increase risk.
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Registrant
- 0001213900-25-048534 (filing_id) — Accession Number
- 20250529 (date) — Filing Date
- Vancouver, BC (location) — Company Headquarters
FAQ
What type of filing is this DEFA14A for InMed Pharmaceuticals Inc.?
This filing is for Definitive Additional Materials related to a Proxy Statement, filed under Schedule 14A.
When was this filing submitted to the SEC?
The filing was submitted on May 29, 2025.
What is the company's primary business classification?
InMed Pharmaceuticals Inc. is classified under Pharmaceutical Preparations [2834].
Where is InMed Pharmaceuticals Inc. located?
The company's business and mailing address is Suite #1445-885 W. Georgia St., Vancouver, BC V6C 3E8, Canada.
Was there a fee associated with this filing?
No fee was required for this filing, as indicated by the checkbox selection.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on May 29, 2025 regarding InMed Pharmaceuticals Inc. (INM).